VASH2 and neoplasm: Moreover, paclitaxel treatment efficacy on LUSC was remarkably improved in combination with EpoY in vivo (Fig. 3), which suggested that blocking TCP activity of VASH2 could inhibit LUSC tumor growth and increase the sensitivity of chemotherapeutic drugs.